ArticleBreast cancer research : BCR2025
Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast tumors have traditionally been categorized into four subtypes. Recent single-cell advancements, however, reveal that tumors can contain multiple subtypes, reflecting intrinsic heterogeneity. Relatedly, whilst the crucial role of cell cycle regulation in cancer development is widely acknowledged, the impact of cell cycle phases on oncogenic signaling within these subtypes remains unresolved. Here, we examine differences in transcriptomic hallmarks across and within cell cycle phases and breast cancer subtypes in two large single-cell cohorts. We show that accounting for cell cycle phases reveals a broader pool of hallmark pathways while preserving those identified when phases are ignored. Moreover, we pinpoint FDA approved drugs that can target hallmarks within specific phase-subtype combinations. This study highlights the critical role of cell cycle phases in advancing our understanding of cancer biology. The distinct mechanisms observed here suggest that targeting these hallmarks may offer a more precise and effective strategy for patient treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.